12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Actos pioglitazone regulatory update

FDA is reviewing the safety of Actos pioglitazone from Takeda after interim data from a long-term trial showed a significantly increased risk of bladder cancer in patients exposed to the diabetes drug for more than 24 months. However,...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >